Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
David RoofehCelia J F LinJonathan GoldinGrace Hyun J KimDaniel E FurstChristopher P DentonSuiyuan HuangZsuzsanna H McMahannull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
TCZ in early SSc-associated ILD with progressive skin disease stabilized FVC% over 48 weeks, independent of the extent of radiographically evident QILD.